63 studies found for:    INCB018424 | Exclude Unknown
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
2 Recruiting Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Drug: TKI
3 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
4 Completed A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 phosphate cream;   Drug: Dovonex® calcipotriene 0.005%;   Drug: Diprolene® AF betamethasone dipropionate 0.05% cream.;   Drug: Placebo cream
5 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
6 Recruiting Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Intervention: Drug: Ruxolitinib
7 Recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
8 Terminated
Has Results
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: Ruxolitinib
9 Active, not recruiting
Has Results
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib
10 Active, not recruiting
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
11 Not yet recruiting A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib
12 Active, not recruiting INCB018424 in Patients With Advanced Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Intervention: Drug: INCB018424
13 Active, not recruiting Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone
14 Completed
Has Results
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
15 Not yet recruiting Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Breast Cancer, Secondary;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
16 Recruiting A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Condition: Myelomonocytic Leukemia
Intervention: Drug: Ruxolitinib
17 Recruiting Ruxolitinib in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
18 Recruiting Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Condition: Polycythemia Vera
Interventions: Drug: Best Available Therapy;   Drug: ruxolitinib
19 Active, not recruiting Phase l/II Study of Ruxolitinib for Acute Leukemia
Condition: Leukemia
Intervention: Drug: Ruxolitinib
20 Recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years